SCHEMBL30471983

SCHEMBL30471983

CCNCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PDE2A O00408 1/20 0.44
KMT2A Q03164 1/20 0.41
POLB P06746 2/20 0.40
DAO P14920 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
MAPK1 P28482 1/20 0.38
MBOAT4 Q96T53 1/20 0.38
BACE1 P56817 1/20 0.37
GLS O94925 1/20 0.36
TRPV3 Q8NET8 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10288360 1.00 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL24258303 0.87 KDM1A (0.46) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL30481847 0.87 KDM1A (0.46) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL24468262 0.83 KDM1A (0.46) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL24468397 0.83 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL30841845 0.83 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL10278513 0.82 KDM1A (0.50) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL23757911 0.82 KDM1A (0.45) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL29685743 0.82 KDM1A (0.45) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL25375893 0.82 KDM1A (0.42) KDM1AMAOAMAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4549442-A1 PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 EP disclosed
CN-119487041-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-02-18 CN disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. 2024-03-28 US disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685727-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 KDM1A 4089/4885MAOA 3525/4885MAOB 3188/4885
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM1A 37/4885MAOA 3279/4885MAOB 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.